The incidence rate and economic burden of community-acquired pneumonia in a working-age population

American Health and Drug Benefits

Volumn 6, Issue 8, 2013, Pages 494-503

  Broulette, Jonah ^a   Yu, Holly ^b   Pyenson, Bruce ^a   Iwasaki, Kosuke ^a   Sato, Reiko ^b  

^a MILLIMAN INC   (United States)

^b Pfzer Specialty Care Business Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGING; ARTICLE; BIOSTATISTICS; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DATA BASE; ECONOMIC ASPECT; EMPLOYEE; EMPLOYER; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HIGH RISK POPULATION; HOSPITAL CARE; HOSPITAL PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; OUTPATIENT; OUTPATIENT CARE; POPULATION RESEARCH; RETIREMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; SOCIAL PROBLEM; UNITED STATES; WORK DISABILITY;

EID: 84886703480     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Mandell LA, Wunderink RG, Anzueto A, et al; For the Infectious Diseases Society of American, and the American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.
2. Nair GB, Niederman MS. Community-acquired pneumonia: an unfinished battle. Med Clin North Am. 2011;95:1143-1161.
3. Brar NK, Niederman MS. Management of community-acquired pneumonia: a review and update. Ther Adv Respir Dis. 2011;5:61-78.
4. Mertz D, Johnstone J. Modern management of community-acquired pneumonia: is it cost-effective and are outcomes acceptable? Curr Infect Dis Rep. 2011;13:269-277.
5. Polverino E, Torres Marti A. Community-acquired pneumonia. Minerva Anestesiol. 2011;77:196-211.
6. Carbonara S, Monno L, Longo B, Angarano G. Community-acquired pneumonia. Curr Opin Pulm Med. 2009;15:261-273.
7. Niederman MS, Luna CM. Community-acquired pneumonia guidelines: a global perspective. Semin Respir Crit Care Med. 2012;33:298-310.
8. Ramirez JA, Anzueto AR. Changing needs of community-acquired pneumonia. J Antimicrob Chemother. 2011;66(suppl 3):33-39.
9. Niederman MS. Community-acquired pneumonia: the U.S. perspective. Semin Respir Crit Care Med. 2009;30:179-188.
10. Hoyert DL, Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep. 2012;61:1-51.
11. Centers for Disease Control and Prevention. National Hospital Discharge Survey. Number of discharges from short-stay hospitals, by first-listed diagnosis and age: United States, 2010. Updates August 22, 2013. www.cdc.gov/nchs/data/nhds/3frst-listed/2010frst3_numberage.pdf. Accessed February 4, 2013.
12. Bonafede MM, Suaya JA, Wilson KL, et al. Incidence and cost of CAP in a large working-age population. Am J Manag Care. 2012;18:380-387.
13. Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community-acquired pneumonia in an employed population. Chest. 2004;125:2140-2145.
14. Birnbaum HG, Morley M, Greenberg PE, et al. Economic burden of pneumonia in an employed population. Arch Intern Med. 2001;161:2725-2731.
15. Birnbaum HG, Morley M, Greenberg PE, Colice GL. Economic burden of respiratory infections in an employed population. Chest. 2002;122:603-611.
16. Polsky D, Bonafede M, Suaya JA. Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults. BMC Health Serv Res. 2012;12:379.
17. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20:820-837.
18. Yu H, Rubin J, Dunning S, et al. Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population. J Am Geriatr Soc. 2012;60:2137-2143.
19. Thomas CP, Ryan M, Chapman JD, et al. Incidence and cost of pneumonia in Medicare beneficiaries. Chest. 2012;142:973-981.
20. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59:1102-1106.
21. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-8):1-24.
22. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39:1642-1650.
23. Kaplan V, Angus DC, Griffn MF, et al. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med. 2002;165:766-772.
24. Cunha BA. Community-acquired pneumonia. Medscape. Updated July 1, 2013. http://emedicine.medscape.com/article/234240-overview#aw2aab6b4. Accessed February 4, 2013.
25. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
26. Wasser T, Yu J, Singer J, et al. Long-term cost consequences of community-acquired pneumonia in adults. Am J Pharm Benefits. 2013;5:e66-e72.
27. Sato R, Gomez Rey G, Nelson S, Pinsky B. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥50 years. Appl Health Econ Health Policy. 2013;11:251-258.
28. Centers for Disease Control and Prevention. Flu vaccination coverage, United States, 2011-12 influenza season. Updated August 15, 2013. www.cdc.gov/fu/pdf/professionals/vaccination/vax-coverage-1112estimates.pdf. Accessed August 12, 2013.
29. Centers for Disease Control and Prevention (CDC). Noninfluenza vaccination coverage among adults-United States, 2011. MMWR Morb Mortal Wkly Rep. 2013; 62:66-72.